Kestra Private Wealth Services LLC Purchases 4,718 Shares of Eli Lilly and Company (NYSE:LLY)

Kestra Private Wealth Services LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 12.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 44,072 shares of the company's stock after purchasing an additional 4,718 shares during the quarter. Eli Lilly and Company comprises 0.6% of Kestra Private Wealth Services LLC's holdings, making the stock its 25th biggest position. Kestra Private Wealth Services LLC's holdings in Eli Lilly and Company were worth $36,400,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Knightsbridge Asset Management LLC grew its position in shares of Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after purchasing an additional 15 shares during the period. LS Investment Advisors LLC grew its stake in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after acquiring an additional 40 shares in the last quarter. Prism Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $207,000. CSM Advisors LLC grew its stake in shares of Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after acquiring an additional 245 shares in the last quarter. Finally, Bfsg LLC grew its stake in shares of Eli Lilly and Company by 1.4% during the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock worth $2,444,000 after acquiring an additional 42 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LLY. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Saturday, June 28th. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Finally, Guggenheim increased their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research note on Friday, July 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $10.28 during trading hours on Friday, hitting $771.78. The company's stock had a trading volume of 3,351,657 shares, compared to its average volume of 3,664,442. The stock has a fifty day simple moving average of $767.03 and a 200-day simple moving average of $800.02. The company has a market capitalization of $731.45 billion, a P/E ratio of 62.80, a PEG ratio of 1.12 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the business earned $2.58 earnings per share. Eli Lilly and Company's revenue was up 45.2% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company's payout ratio is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.